PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the release of its financial results for Q1 2021 on May 13, 2021, prior to market open. Following this release, management will conduct a conference call at 8:00 am ET to discuss the results and provide a business update. The call will also be available as a live webcast, and an archived version will be accessible on the company’s website for six months. PDS Biotech focuses on developing cancer therapies and vaccines using its proprietary Versamune^® T-cell activating technology.

Positive

• Scheduled conference call to discuss Q1 2021 financial results.
• Versamune^® technology is unique in activating immune responses.

Negative

• None.

FLORHAM PARK, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® T-cell activating technology, today announced that the Company will release financial results for the first quarter of 2021 on Thursday, May 13, 2021, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am ET on Thursday, May 13, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotech’s website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13718826.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune^® T-cell activating technology platform. Versamune^® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

FAQ

When will PDS Biotechnology release its financial results for Q1 2021?

PDS Biotechnology will release its financial results for Q1 2021 on May 13, 2021, before the market opens.

What time is the conference call for PDS Biotechnology's Q1 financial results?

The conference call is scheduled for 8:00 am ET on May 13, 2021.

How can I access the PDS Biotechnology conference call?

You can access the conference call by dialing 877-407-3088 (U.S.) or 201-389-0927 (International), or by visiting their investor relations page for a live webcast.

Where can I find the archived version of the PDS Biotechnology conference call?

The archived version of the conference call will be available on PDS Biotech’s website for six months after the live event.